Evidence map›Paper›PMID 35199858›Full record

ArticleClinical and experimental pharmacology & physiology2022

Challenges with the proposed ACE2 activation mechanism of diminazene aceturate.

Shiva Hadi Esfahani, Vardan T Karamyan

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Clinical and experimental pharmacology & physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shiva Hadi EsfahaniDepartment of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.
Vardan T KaramyanDepartment of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.ORCID 0000-0003-0050-6047
Texas Tech University · US

Funding

Development and Characterization of Small Molecule Activators of Peptidase Neurolysin for Stroke TherapyR01NS106879 · NINDS · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI Thomas J Abbruscato, Vardan T. Karamyan · 2018 to 2026
$4.2M
NINDS NIH HHS R01 NS106879
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Angiotensin-Converting Enzyme 2DiminazeneRenin-Angiotensin SystemAngiotensin-Converting Enzyme 2Diminazenediminazene aceturate

Identifiers

PMID35199858
OpenAlexW4213442021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.